Journal Club ft. NEJM publications   

How do outcomes compare between patients receiving adjuvant vs neoadjuvant therapy? How are you deciding when to offer one over the other?

Do you base your decision on extent of residual disease?  Does the use of preoperative immunotherapy have an impact on surgical site size or hea...

How do comorbid conditions weigh into this decision?

Do you view the difference threshold on itch NRS as clinically meaningful to patients?

For example, there was recently a study in JAMA showing efficacy in cholestatic pruritis.

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

ADVOCATE trial

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

In the ADVOCATE trial, patients were not re-dosed with rituximab.